<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>mAbs reactive with <z:chebi fb="0" ids="53000">epitopes</z:chebi> expressed on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vessels were evaluated as universal delivery agents of <z:chebi fb="7" ids="16670">peptides</z:chebi> with vasoactive properties to enhance the uptake of macromolecules in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Unlike other reported approaches to target <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vessels, a mAb designated TV-1 targets a basement membrane antigen that is found in <z:hpo ids='HP_0000001'>all</z:hpo> tissues but that is accessible only in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vessels, making it an alternative vehicle for the delivery of biologically active <z:chebi fb="7" ids="16670">peptides</z:chebi> to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>A panel of 30 monoclonal and polyclonal antibodies was screened by immunohistochemistry on sections of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, <z:mpath ids='MPATH_458'>normal</z:mpath> vascular endothelium, and connective tissues </plain></SENT>
<SENT sid="3" pm="."><plain>Five antibodies were chosen for in vivo evaluation, including two antifibronectin antibodies (TV-1, HFN 7.1), one anti-basic fibroblast growth factor antibody (anti-BFGF), and two antibodies reactive with a mesenchymal cell antigen (TP-1, TP-3) </plain></SENT>
<SENT sid="4" pm="."><plain>Three <z:mp ids='MP_0003815'>nude</z:mp> mouse <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models characterized by varying degrees of vascularization (low to high) were used </plain></SENT>
<SENT sid="5" pm="."><plain>After chemical conjugation to interleukin 2 (IL-2), these antibodies were used to pretreat <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing <z:mp ids='MP_0003815'>nude</z:mp> mice 3 h before injection with a radiolabeled mAb directed to the transplanted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Pretreatment with TV-1/IL-2 or HFN 7.1/IL-2 produced a 3-fold higher <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake of radiolabel compared to control mice pretreated with mAb alone </plain></SENT>
<SENT sid="7" pm="."><plain>The other three vasoactive immunoconjugates failed to show significant increases in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models </plain></SENT>
<SENT sid="8" pm="."><plain>When TV-1/IL-2 was compared with the specific vasoconjugate (Lym-1/IL-2) as a pretreatment in the Raji <z:hpo ids='HP_0002665'>lymphoma</z:hpo> model, which has low vascularization, TV-1/IL-2 yielded approximately 60% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake seen with Lym-1/IL-2 </plain></SENT>
<SENT sid="9" pm="."><plain>In comparison, pretreatment with TV-1/IL-2 in the LS174T colon <z:mp ids='MP_0002038'>carcinoma</z:mp> model, which has high vascularization, yielded approximately the same <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake seen with the B72.3/IL-2 vasoconjugate, which directly targets the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="10" pm="."><plain>These studies demonstrate that a mAb directed against fibronectin in the endothelial subcellular matrix can be used to deliver vasoactive agents to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>